Cyltezo

Boehringer Ingelheim Pharmaceuticals, Inc, announces US Food and Drug Administration approval of the biosimilar Cyltezo (adalimumab-adbm) in a prefilled syringe for the treatment of plaque psoriasis and psoriatic arthritis as well as other chronic inflammatory diseases. Cyltezo is not commercially available at this time. For more information, visit www.boehringer-ingelheim.us.

Facing Forward App

Cutanea Life Sciences, Inc, introduces Facing Forward, a mobile app for patients with acne to track their treatment with Aktipak (erythromycin and benzoyl peroxide) Gel 3%/5%. The app features a camera function for users to take photographs to track their progress, dosing reminders, prescription refill reminders, acne information resources, and a compliance report so that the physician can determine if the patient is using the medication properly. This app is available free through the App Store or Google Play. For more information, visit www.cutanea.com.

Glytone Dark Spot Corrector

Pierre Fabre Dermo Cosmetique USA introduces the Glytone Dark Spot Corrector, a brightening formula with hydroquinone 2% to help reduce the appearance of pigmentation changes due to pregnancy, use of oral contraceptives, skin aging, or photodamage. It also contains glycolic acid to exfoliate dead cells from the skin's surface and kojic acid to brighten the skin. For more information, visit www.glytone-usa.com.

Loyon

IntraDerm Pharmaceuticals, a division of Sonoma Pharmaceuticals, Inc, announces US commercialization of Loyon to manage and relieve the scaling, erythema, and pruritus associated with various types of dermatoses including seborrhea and seborrheic dermatitis. Loyon is a combination of the dry emollient Cetiol CC and the medical silicone oil dimethicone. It is a fast and effective treatment for scaling associated with seborrheic dermatitis or psoriasis, which impacts patient quality of life. This product received 510(k) clearance from the US Food and Drug Administration in March 2017. For more information, visit www.intraderm.com.

Stelara

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adolescents (≥12 years of age) who are candidates for phototherapy or systemic therapy. Stelara was first approved for the treatment of plaque psoriasis in adults in 2009. For more information, visit www.stelarahcp.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.